Equity Research Biotechnology

Should You Buy Ascendis Pharma A/S Stock in 2026?

By CirclFi Research Team · · Updated · 3/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Ascendis Pharma A/S (ASND) occupies a solid middle-ground position with a Quality of Company score of 6.5/10. At the current market price of $239.77, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 0 of 3 CirclFi valuation models project upside for Ascendis Pharma A/S (ASND) at $239.77 — the model consensus leans bearish, with a Quality Score of 6.5/10 and Value-Trap risk of 7/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 3 of 3 models suggest overvaluation — majority bearish
  • Quality Score: 6.5/10 — Moderate — mixed signals
  • Value Trap Risk: 7/100 — Minimal — healthy fundamentals
  • Fair Value Range: $21.53 – $42.21 (96% spread)

Bullish Models

0 / 3

Bearish Models

3 / 3

Quality Score

6.5 /10

Moderate — mixed signals

Value Trap Risk

7 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

3 /13
Active Models

Avg. confidence: 52%

What Is the Investment Case for Ascendis Pharma A/S (ASND) in 2026?

What Is the Bull Case vs the Bear Case for Ascendis Pharma A/S (ASND)?

Bull case versus bear case for Ascendis Pharma A/S (ASND) at $239.77, derived from 3 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $21.53 target (-91.0%)
No active model projects meaningful upside for ASND at $239.77. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $21.53 (-91.0%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: dilutive capital raises represents a meaningful risk for Ascendis Pharma A/S and its Biotechnology peers.

How Does ASND Compare to Its Biotechnology Peers?

TVTX Travere Therapeutics
6.5
BEAM Beam Therapeutics In
6.5
NTRB Nutriband Inc.
6.5
FBIO Fortress Biotech, In
6.5
VIR Vir Biotechnology, I
6.5
ARDX Ardelyx, Inc.
6.5
PULM Pulmatrix, Inc.
5.4
LBRX LB Pharmaceuticals I
4.7

Valuation data pages: TVTX · BEAM · NTRB · FBIO · VIR · ARDX · PULM · LBRX · PPCB · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like ASND on Quality?

Closest companies to ASND’s Quality of Company score of 6.5/10, across all industries.

Which Biotechnology Screens Does ASND Appear In?

Why Do CirclFi’s 3 Models Disagree on ASND?

Spread

96%

Fair Value Range

$21.53 – $42.21

A 96% spread represents moderate disagreement. The models agree on direction but differ on magnitude.

Most Bullish

Regime Cross

$42.21 (-82.4%)

Most Bearish

Bayesian DCF

$21.53 (-91.0%)

What Are the Biggest Risks of Buying ASND Stock?

Bearish Consensus

3/3 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ASND Data Page →

So Is Ascendis Pharma A/S (ASND) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Ascendis Pharma A/S at $239.77. 3/3 models flag overvaluation, median fair value sits at $24.24 (-89.9%), and the risk-reward profile appears unfavorable. Quality at 6.5/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Ascendis Pharma A/S's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ASND Stock?

Should I buy ASND stock right now?

Based on CirclFi's multi-model analysis, 0 of 3 models see upside for ASND at $239.77. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Ascendis Pharma A/S?

Key risks include: limited model coverage (3/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does ASND compare to its competitors?

Among Biotechnology peers, ASND holds a Quality Score of 6.5/10. Comparable companies include TVTX (QOC 6.5), BEAM (QOC 6.5), NTRB (QOC 6.5). The relative ranking helps investors identify whether ASND offers better fundamental quality than alternatives in the same sector.

Is ASND a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ASND's Quality Score of 6.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ASND at?

CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $21.53 to $42.21. At $239.77, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ASND.

View ASND Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →